The FDA has signed off on emergency use of Eli Lilly’s (LLY +2.6%) qualitative (yes/no answer) molecular test for SARS-CoV-2. The use of laboratory developed test (LDT) is restricted to the company’s diagnostics lab at its corporate campus in Indianapolis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.